BlockStreet (BSB) fluctuates 59.5% in 24 hours: suspected team sell-off and high-volume speculation drive severe volatility
Bitget Pulse2026/04/30 22:03Volatility Brief
BSB's price in the past 24 hours touched a low of $0.40437 and a high of $0.645, currently sitting at $0.60969, with fluctuations reaching as high as 59.5%. Trading volume significantly expanded to around $84.7 million, and open interest (OI) in derivatives once surged by 82%. However, with over $500 million in liquidations, there are clear signs of net capital outflow.
Summary of Abnormal Movements
- Suspected Team Sell-off: Reports from 20 hours ago indicate a suspected late-night team sell-off of the Binance Alpha project BSB, resulting in a 60% price plunge and a sharp drop from the peak.
- High Volume Speculation and Derivatives Liquidations: In the past 24 hours, trading volume soared above $133 million, with leveraged trading amplifying volatility and drastic OI changes (once +82% before crashing), triggering a chain reaction of liquidations and corrections.
- On-chain Capital Movements: Net inflow reached $850,000 but recently turned to outflows, with increased whale sell pressure intensifying price swings.
Market Views and Outlook
Overall community sentiment is cautious. Traders note the 24-hour RSI dropped from 79.98 (overbought) to 30 (oversold), and a long/short ratio of 0.93 suggests potential for a short squeeze, but the risk of a pullback is high, emphasizing that “the structure is fragile and further corrections should be watched for.” Analysts highlight that the high volatility is driven by speculation, with short-term oscillations likely to continue and no clear upward catalyst on the horizon.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is provided for reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
Ledger CTO urges crypto holders to update iPhones after DarkSword exploit revealed
Crypto ICOs Left in Limbo After CLARITY Act Fails in Senate